Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury by Mikus, Maria et al.
MISCELLANEOUS
Elevated levels of circulating CDH5 and FABP1 in association with human
drug-induced liver injury
Maria Mikus1, Kimi Drobin1, Marcus Gry2, Julie Bachmann1, Johan Lindberg2, Getnet Yimer3, Eleni Aklillu4,
Eyasu Makonnen3, Getachew Aderaye5, James Roach6, Ian Fier6, Caroline Kampf7, Jens G€opfert8, Hugo Perazzo9,
Thierry Poynard9, Camilla Stephens10, Raul J. Andrade10, M Isabel Lucena10, Nadir Arber11, Mathias Uhlen1,
Paul B. Watkins12, Jochen M. Schwenk1, Peter Nilsson1,a and Ina Schuppe-Koistinen13,14,a
1 Affinity proteomics, SciLifeLab, School of Biotechnology, KTH-Royal Institute of Technology, Stockholm, Sweden
2 Global Safety Assessment, Molecular Toxicology, Former AstraZeneca R&D, S€odert€alje, Sweden
3 Department of Pharmacology, Addis Ababa University, Addis Ababa, Ethiopia
4 Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden
5 Department of Internal Medicine, Addis Ababa University, Addis Ababa, Ethiopia
6 Momenta Pharmaceuticals, Cambridge, MA, USA
7 Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden
8 Biochemistry Department, Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany
9 Hepatology Department, Ho^pital Pitie-Salpe^triere, Paris, France
10 UGC Gastroenterologia y Hepatologia y Serv Farmacologıa Clınica, IBIMA, Hospital U Virgen de la Victoria, University of Malaga, Malaga, Spain
11 The Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
12 Schools of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
13 Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
14 AstraZeneca R&D, Innovative Medicines Personalised Healthcare & Biomarkers, SciLifeLab, Stockholm, Sweden
Liver Int. 2017; 37: 132–140. DOI: 10.1111/liv.13174
Abstract
Background & Aims: The occurrence of drug-induced liver injury (DILI) is a major issue in all phases of drug development.
To identify novel biomarker candidates associated with DILI, we utilised an affinity proteomics strategy, where antibody sus-
pension bead arrays were applied to profile plasma and serum samples from human DILI cases and controls. Methods: An
initial screening was performed using 4594 randomly selected antibodies, representing 3450 human proteins. Resulting can-
didate proteins together with proposed DILI biomarker candidates generated a DILI array of 251 proteins for subsequent tar-
get analysis and verifications. In total, 1196 samples from 241 individuals across four independent cohorts were profiled:
healthy volunteers receiving acetaminophen, patients with human immunodeficiency virus and/or tuberculosis receiving
treatment, DILI cases originating from a wide spectrum of drugs, and healthy volunteers receiving heparins. Results: We
observed elevated levels of cadherin 5, type 2 (CDH5) and fatty acid-binding protein 1 (FABP1) in DILI cases. In the two longi-
tudinal cohorts, CDH5 was elevated already at baseline. FABP1 was elevated after treatment initiation and seemed to
respond more rapidly than alanine aminotransferase (ALT). The elevations were verified in the DILI cases treated with various
drugs. In the heparin cohort, CDH5 was stable over time whereas FABP1 was elevated. Conclusions: These results suggest
that CDH5 may have value as a susceptibility marker for DILI. FABP1 was identified as a biomarker candidate with superior
Abbreviations
ALP, alkaline phosphatase; ALT, alanine aminotransferase; APAP, acetaminophen; AST, aspartate aminotransferase; AUC, area under the curve;
CDH5, cadherin 5, type 2; DILI, drug-induced liver injury; FABP1, fatty acid-binding protein 1; HIV, human immunodeficiency virus; HV, healthy
volunteers; MFI, median fluorescence intensity; TB, tuberculosis.
Correspondence
Ina Schuppe Koistinen, SciLifeLab Box 1031, SE-17121 Solna, Sweden
Tel: +46852481418 (PN); +46737121642 (ISK)
e-mails: peter.nilsson@scilifelab.se and ina.schuppe-koistinen@scilifelab.se
aCorresponding authors and shared senior authors.
Handling Editor: Carmen Berasain
Received 3 July 2015; Accepted 13 May 2016
Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1111/liv.13174/suppinfo
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Liver International (2017)
© 2016 The Authors Liver International Published by John Wiley & Sons Ltd132
Liver International ISSN 1478-3223
characteristics regarding tissue distribution and kinetics compared to ALT but likely with limited predictive value for the
development of severe DILI. Further studies are needed to determine the clinical utility of the proposed markers.
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Drug-induced liver injury (DILI) is the single leading
cause for termination of drug development and safety-
related withdrawal of approved drugs from the market
(1). In clinical practice, it accounts for more than 50%
of liver failure cases and represents a major safety issue
for patients (2). In some patients, DILI can cause severe
injury leading to acute liver failure that can be life-threa-
tening and require liver transplantation (3, 4). The esti-
mated incidence of DILI is about 14 cases per 100 000
inhabitants (5). Because of the low incidence of DILI,
there are often too few individuals in a clinical trial to
detect the adverse effects (2).
The biomarkers commonly used to detect liver injury
are serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase (ALP)
and total bilirubin levels. Serum elevations of ALT and
AST indicate hepatocellular damage and increased ALP
is related to hepatobiliary injury. Those markers are use-
ful for the diagnosis of severe DILI, but lack the ability
to differentiate between severe and mild cases at the
onset of DILI and predict if a patient will adapt or
develop severe injury of the liver. Mild elevations of liver
enzymes are commonly observed and may be because of
different factors, such as diet, exercise or fatty liver. Fur-
thermore, mild elevations of ALT can be observed after
treatment with drugs that do not have the potential to
cause severe DILI and in many cases those elevations are
of transient nature and will resolve despite of continued
treatment (6). There are no adequate predictive methods
or reliable biomarkers for DILI and the diagnosis is a
matter of excluding other conditions, such as viral hep-
atitis, and finding a causative connection between drug
exposure and potential drug-related injury (3, 4). There
is a clear need for more specific markers for liver injury
compared with current standard tests and markers that
predict susceptibility to DILI of individual patients.
In the present study, we aimed at the discovery of
novel biomarkers for DILI by the application of affinity
proteomics to human DILI cohorts based on a variety of
drug treatments. Affinity proteomics uses capture
reagents such as antibodies for comparative proteomic
characterization of samples and has proven successful in
various previous studies within e.g. malaria and multi-
ple sclerosis (7, 8). Antibodies with relevance for liver
toxicity were used in exploratory multiplexed assays and
biomarker candidates were identified based on DILI
cases from a healthy volunteer (HV) cohort treated with
acetaminophen (APAP) and a cohort with patients trea-
ted for human immunodeficiency virus (HIV) and/or
tuberculosis (TB). The results were subsequently verified
using DILI cases from a variety of drug treatments col-
lected by the SAFE-T consortium, a publicprivate
partnership under the framework of the EU Innovative
Medicines Initiative (9) that focuses on the clinical qual-
ification of biomarkers for drug-induced injuries to the
liver, kidney and vascular system. Furthermore, the
findings were compared with asymptomatic liver
enzyme elevations induced by heparins that have not
been associated with clinical significant liver injury.
See supplementary information for Materials and
methods.
Results
To enable a broad-scale screening and protein profiling
for the potential identification of novel biomarker can-
didates associated with DILI, we here set out an explo-
rative affinity proteomics strategy. An initial non-
targeted discovery screening that encompassed 4594
antibodies targeting 3450 unique proteins, representing
approximately 17% of the human gene products, was
combined with targeted profiling using a carefully
designed DILI array. The screening and verification
strategy was based on the analysis of 1196 plasma and
serum samples from 241 individuals divided across four
independent cohorts (HV APAP, HIV/TB, SAFE-T DILI
and HV Heparin, see Supplementary demographics
tables and Table S2) in combination with an antibody
suspension bead array approach (Fig. 1).
Design of the DILI antibody array
In the non-targeted discovery stage, a screening array of
4594 antibodies and a subset of the HV APAP cohort
Key points
• An affinity proteomics screening using 4594 anti-
bodies was performed followed by a targeted array
for profiling of 241 individuals (1196 samples) from
four independent cohorts with drug-induced liver
injuries (DILI).
• CDH5 (cadherin 5, type 2) was found to be ele-
vated in DILI cases and already in baseline samples of
the longitudinal cohorts.
• FABP1 (fatty acid-binding protein 1) was found to
be elevated in DILI cases and showed a treatment-
dependent profile in the longitudinal cohorts.
• We propose CDH5 as a potential susceptibility
marker and FABP1 as a potential marker with superior
tissue distribution and kinetics compared to ALT.
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(day 2, baseline) were used. The baseline samples served
to identify potential DILI susceptibility markers that
could be included in the DILI array. This resulted in the
selection of 113 antibodies. These were in combination
with a selection of antibodies from previous in-house
protein profiling efforts and thorough literature mining,
pathway analysis, gene and protein expression data and
information on liver-enriched expression of proteins
from the Human Protein Atlas project (10) used to gen-
erate the targeted DILI array of 287 antibodies repre-
senting 251 proteins (Table S1).
Experimental profiling setup
In the targeted discovery stage, the DILI array was used
to profile two independent cohorts of longitudinal
design, the complete HV APAP cohort (355 samples, 14
cases, 15 controls, 13 time points) and the HIV/TB
cohort (472 samples, 38 cases and 38 controls, 7 time
points). In a first verification, the same cohorts were
again profiled but with a smaller set of antibodies
defined by the results from the targeted discovery stage
and incorporating additional antibodies per protein,
resulting in a set of 91 antibodies targeting 47 proteins
(Table S3). The SAFE-T DILI cohort (88 samples, 26
cases, 62 controls) was included in Verification 2, to
replicate the initial findings. In Verification 3, an even
smaller set of 34 selected targets represented by 61 anti-
bodies and more antibodies per protein target was used.
Finally, the HV Heparin cohort (281 samples, 48 cases,
6 time points), was profiled in Verification 4 and
repeated.
Elevated levels of CDH5 and FABP1
Two proteins, CDH5 (cadherin 5, type 2) and FABP1
(fatty acid-binding protein 1), were identified to be ele-
vated in DILI cases. The longitudinal dependence of
these markers was first investigated by profiling serum
and plasma from the HV APAP and HIV/TB cohort,
covering a time frame of 14 days and 12 weeks respec-
tively. In HV APAP, CDH5 showed elevated median
levels in DILI cases already in the pre-dose/baseline
samples (day 1–3). Although only significant at day 11,
the trend of increased levels was sustained across the
studied time frame including time points of dosing as
well as during washout with the exception of day 6. The
same trend with baseline-elevated levels was observed in
the HIV/TB cohort, with significant differences for week
2 and 4 as well as for week 8 and 12 (Fig. 2b). ALT and
FABP1 displayed a treatment-dependent appearance
with increasing levels in DILI cases after initiation of the
dosing in both the HV APAP and the HIV/TB cohort
(Fig. 2a+c). In HV APAP, a significant elevation in
FABP1 was observed one day prior to ALT (day 8 com-
pared to day 9). The elevation for both remained signifi-
cant during the continued dosing as well as after
treatment had stopped. Interestingly, towards the end of
the study period, FABP1 levels started to decrease (com-
pare day 9 with day 14) whereas ALT remained
unchanged. For the HIV/TB cohort, a significantly
higher level of FABP1 was found for week 6 and
onwards. The elevated levels were confirmed in the
SAFE-T DILI cohort with significant differences of 105
and 1010 for CDH5 and FABP1 respectively (Fig. 2b,
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Fig. 1. Study design. Overview of the study design with information regarding the various cohorts (number of samples and collection time
points) and the antibody arrays (number of antibodies and unique protein targets) used in the different stages.
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c). Furthermore, profiling of the Heparin cohort showed
an elevation in FABP1 levels across the studied time
frame whereas CDH5 levels were relatively stable
(Fig. 3b,c).
As shown in Table S2, the HIV/TB cohort was bal-
anced in age and gender. The HV APAP had too small
sample size to perform stratified analysis. When the
SAFE-T cohort was stratified by gender or age, same
trends of fold changes between cases and controls were
observed for both markers although not significant in
all age groups (Fig. S1 and S2).
To assess the diagnostic power of CDH5 and FABP1,
receiver operating characteristic analysis was performed
on the SAFE-T DILI cohort, yielding an area under the
curve (AUC) of 0.74 and 0.94 respectively. ALT, which
was used for classification of DILI, gave an expected
AUC of 1 in this sample material. Combining CDH5
and FABP1 in the analysis did not further improve the
AUC.
Target verification and distribution
To demonstrate the reproducibility in measuring CDH5
and FABP1, the average Pearson correlation taken over
the different cohorts was determined as 0.85 and 0.95
respectively. For correlation plots between repeated
experiments, see Figure S3.
Antibody targeting with HPA030562 and HPA028275
for CDH5 and FABP1, respectively, was confirmed with
Western blot of serum samples from the SAFE-T DILI
cohort, a recombinant CDH5 standard and FABP1
overexpression lysate. Bands at the predicted molecular
mass were detected (Fig. S4). Further evidence of on-
target detection was given by the comparison to bead-
based sandwich immunoassays (Fig. S5).
The presence, distribution and abundance of CDH5
and FABP1 in relation to protein and RNA expression
were investigated in healthy human tissue. Immunohis-
tochemical analysis of liver, kidney, heart muscle and
skeletal muscle tissue using anti-FABP1 antibodies
showed strong protein expression in the hepatocytes but
no staining of the bile duct cells. In kidney, FABP1
expression was present in cells of the tubules but not in
cells of the glomeruli. No staining was detected in myo-
cytes of either heart or skeletal muscle tissue (Fig. 4).
On a more global level, FABP1 showed protein expres-
sion in seven of 83 analysed healthy tissue cell types. In
addition to high and medium expression levels in liver
and kidney, medium levels were also seen for the diges-
tive tract (duodenum, small intestine, appendix, colon
and rectum). Staining using anti-CDH5 antibodies
revealed protein expression in all four tissues (Fig. 4).
More globally, protein expression of medium to high
levels in 54 of 81 normal tissue cell types was observed.
Transcriptome analysis using RNA sequencing showed
highest expression of FABP1 in liver tissue followed by
duodenum, small intestine and colon. CDH5 was found
in all tissues except the bone marrow, with placenta,
lung and adipose tissue being the highest ranked
(Fig. S6).
Discussion
In the current study, affinity proteomics was applied to
profile plasma and serum samples from human DILI
cases and controls. We identified two potential candi-
date markers for DILI. They each showed different char-
acteristics that may be useful in prediction or diagnosis.
Our screening and verification strategy was based on
samples from 241 individuals divided across four inde-
pendent cohorts, comprising in total 1196 samples.
Firstly, a cohort of healthy volunteers receiving acetami-
nophen (HV APAP cohort) and a cohort of patients
with HIV and/or TB receiving treatment were profiled
(HIV/TB cohort). Both of these cohorts included
repeated measurements of each individual over time
covering the time before and after treatment initiation,
allowing assessment of the longitudinal dependence of
biomarkers and providing potential to find markers that
can predict, diagnose and monitor DILI. Secondly, a
cohort where DILI was confirmed at the time of sam-
pling (SAFE-T DILI cohort) was used to assess a first
diagnostic power of biomarkers found in the screening.
Finally, potential markers were investigated in a cohort
of healthy volunteers receiving heparins (HV Heparin
cohort) for further evaluation in a setting with asymp-
tomatic and transient ALT elevations. In the end, two
proteins were identified to show elevated levels in the
DILI cases.
CDH5 encodes a calcium-dependent cell adhesion
protein, cadherin-5 (also called VE-cadherin), that is
specific to endothelial cells and a major component of
endothelial adherens junctions. It plays a key role in
endothelial cell biology and is expressed in blood vessels
throughout the body. Through both its adhesive and
signalling properties, CDH5 maintains the balance
between intercellular junction plasticity and integrity, a
requirement for endothelial cells to maintain proper
barrier function of blood vessels while still being capable
of responding to inflammatory and growth factor sig-
nalling (11). Endothelial dysfunction is a hallmark of
many pathological and disease states, including inflam-
mation, atherosclerosis, hypertension, diabetes and
tumour metastasis. Elevated levels of soluble CDH5
have been reported to be associated with diabetic
retinopathy and coronary atherosclerosis (12, 13). How-
ever, the mechanisms involved in this process were not
studied. Furthermore, increased levels of soluble CDH5
were shown to be associated with poor outcome in sev-
ere sepsis (14). In rheumatoid arthritis patients, soluble
CDH5 correlated with disease activity (15). The study
also showed that tumour necrosis factor (TNF) alpha
induced time-dependent shedding of CDH5 into cell
media of human umbilical vein endothelial cell cultures.
In addition to TNF alpha, numerous other endogenous
mediators of inflammation have been shown to increase
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Fig. 2. Protein profiles in the HV APAP, HIV/TB and SAFE-T DILI cohorts. (a) ALT, (b) CDH5 and (c) FABP1 in DILI cases and controls of three
independent cohorts measured with a standard clinical test (enzymatic activity assay) or with the antibody suspension bead array assay. In
HV APAP, acetaminophen was administered between day 4 and day 11. For patients in HIV/TB, the treatment started at week 1 and contin-
ued across the analysed time frame. Antibodies targeting CDH5 and FABP1 detected elevated levels of the proteins in DILI cases in all the
three cohorts. * P < 0.05, ** P < 0.01 based on Wilcoxon’s rank sum tests.
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microvascular permeability by targeting CDH5 (16).
The cleavage of the CDH5 extracellular domain by pro-
teinases is one of the molecular mechanisms involved in
neutrophil progression across the endothelial junctions
during inflammatory processes and endothelial apopto-
sis (17). Based on our finding of elevated levels of sol-
uble CDH5 in blood from DILI cases compared to
controls prior to treatment with different drugs, we sug-
gest that the protein may have use as a potential suscep-
tibility marker for DILI that reflects an ongoing
inflammation. It remains to be proven that the measure-
ment of CDH5 in parallel with conventional liver injury
markers improves the identification of individuals at
risk to develop DILI prior to drug treatment.
Fatty acid-binding proteins belong to a family of
intracellular lipid-binding proteins that are involved in
uptake, transport and metabolism of fatty acids. FABP1
encodes a fatty acid-binding protein found in hepato-
cytes of the liver, but in small quantities, also in kidney
(proximal tubules) and small intestine as confirmed by
the immunohistochemistry data using Human Protein
Atlas antibodies. Tissue content of FABP1 in liver tissue
is 2.7 mg/g and the content in human intestine ranges
from 26 to 198 lg/g (18). In previous studies, urinary
FABP1 levels were better suited to allow the accurate
and earlier detection of both histopathological and
functional kidney injuries compared with conventional
renal markers (19, 20). It was also proposed as a predic-
tive serum marker for recovery of graft function after
kidney transplantations (21). In context of the liver,
FABP1 has been proposed as a sensitive serum marker
of acute hepatocellular damage in liver transplant recipi-
ents (22) and a diagnostic marker to detect liver injury
because of chronic Hepatitis C infection (23). In a con-
trolled trial, FABP1 was used in the place of aminotrans-
ferases as a more sensitive alternative to detect small
differences in hepatocellular injury that can be induced
during liver surgery. When hepatocytes are damaged,
FABP1 is released to the circulation (24). Some factors
that will affect the plasma concentration of a biomarker
for liver injury are the tendency for the biomarker to be
released during liver injury, its half-life and stability in
plasma and the relative abundance in the liver compared
with other organs (25). FABP1 makes up 1–5% of the
cytosolic protein content in hepatocytes (26) and with a
molecular mass of 14 kDa it has a plasma half-life of
11 min before cleared by the kidneys (27). This can be
compared to ALT, which is a relatively large molecule
(96 kDa) with tissue expression in liver, kidney, pan-
creas, heart and skeletal muscle (28) and a half-life of
40–60 h (29). Although FABP1 exhibits extrahepatic
expression, one major advantage compared to ALT as a
biomarker for DILI is the lack of expression in cardiac
and skeletal muscle tissue (Fig. 4). FABP1 could there-
fore serve as a complement to ALT and add additional
information when muscle injury cannot be excluded as
a cause for increased ALT. The low molecular mass,
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Fig. 3. Protein profiles in the HV Heparin cohort. (a) ALT, (b) CDH5
and (c) FABP1in DILI cases of the HV Heparin cohort. The profiles
for CDH5 were relatively constant across the studied time points,
whereas profiles for FABP1 showed a time-dependent elevation
comparable to that of ALT. Heparin was administered from day 1
(baseline) to day 5 (and serum samples collected before dosing).
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high relative abundance in the liver and the low serum
baseline levels together with a short half-life in the circu-
lation make FABP1 a promising new biomarker for an
ongoing liver injury. However, in the HV Heparin
study, FABP1 elevations correlated very well with ALT
serum levels. Therefore, a use of FABP1 as a prognostic
biomarker that distinguishes between patients with
transient ALT elevations that adapt to the treatment and
those that progress to severe DILI cannot be proposed.
This study has its main limitation in the difficulty to
access DILI samples. DILI is a rare clinical event. A
number of international collaborations, such as the
Spanish DILI Registry or the Drug-induced Liver Injury
Network, have been created to establish large patient
databases as well as a standardized case definition of
DILI. Still, the access to well-characterized clinical sam-
ples from DILI cases is the main limiting factor for the
discovery and qualification of new DILI biomarkers.
Furthermore, the SAFE-T DILI cohort was based on a
large heterogeneity of causative drugs collected during
the DILI episode without available baseline samples.
Relatively small liver enzyme elevations were observed
in the HV APAP cohort. Here, subjects received the
therapeutic dose of 4 g APAP per day and responders
showed transient elevations lower than in cases of APAP
overdose. The dosing was also discontinued if ALT or
AST reached >39 the upper limit of normal. The HIV/
TB cohort also showed small liver enzyme elevations.
Direct comparison of the extent of an increase in ALT
between the healthy and patient cohorts may not be
applicable. A slight increase in ALT and AST level is
more damaging or fatal in sick immunocompromised
HIV and TB patients. In most cases, this rise is accom-
panied by clinical symptoms of liver toxicity and conse-
quently treatment is discontinued before ALT reaches
the levels observed in the HV APAP or SAFE-T cohort.
However, for both the HV APAP and HIV/TB cohorts
the observed time course of DILI was valuable. Other
limitations of the study are an imbalance in age and
gender distributions as well as the slightly varying DILI
case definition used for the different cohorts, as the
standardization in case definition has evolved during
the course of the study.
This exploratory study aimed to identify potential
protein markers that could have use as DILI biomark-
ers irrespective of the drug inducing the injury. The
antibody suspension bead array assay in the employed
format is a method for relative quantification. The
format is convenient in the discovery stages of bio-
marker research, generating multiplex data for hun-
dreds of proteins in hundreds of samples in one
single assay. Although it could be of interest to reveal
potential drug-related differences in the proteins
across the four cohorts or within cohorts, the division
of subjects into subgroups of agents would generate
groups too small to be able to draw any conclusion.
The underlying disease would also need to be consid-
ered leading to further subgroups. In addition, this
would demand that the same DILI criteria were used
for all cohorts and would require absolute quantitative
data. For the same reasons, comparisons between
cohorts were not possible.
Fig. 4. Immunohistochemical staining. Immunohistochemistry analysis using anti-FABP1 and anti-CDH5 antibodies showed cytoplasmic
expression patterns in liver and kidney. Skeletal and heart muscle showed negative or weak protein expression in myocytes for both candi-
dates. CDH5 expression was observed in blood vessels in all tissues included.
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In summary, this biomarker discovery study has been
based on affinity proteomics using human samples from
both healthy volunteers and patients with DILI caused
by a wide spectrum of therapeutical agents. We decided
here to utilise a very stringent approach by only focus-
ing on those proteins that were differentiated in all four
cohorts. Two biomarker candidates were thereby identi-
fied as significantly elevated across the different DILI
studies. CDH5 may potentially have use as a susceptibil-
ity marker for DILI. FABP1 showed superior character-
istics regarding tissue distribution and kinetics
compared to ALT but limited predictive value for the
development of severe DILI. We propose CDH5 and
FABP1 as complementary markers to ALT. Both bio-
marker candidates have been taken up in the clinical
biomarker qualification performed by the SAFE-T con-
sortium. Clinically applicable ELISA assays have been
validated according to the SAFE-T biomarker qualifica-
tion strategy for large-scale analysis of clinical samples.
Further analysis of CDH5 and FABP1 in comparison to
and in combination with current standard assays in
samples from large cohorts of healthy volunteers,
patients with drug- and none drug-induced liver injury
and with common disorders is currently ongoing to
establish the performance characteristics and potential
use for CDH5 and FABP1 as biomarkers. Finally, the
safety biomarker community together with regulators
will need to determine the utility of these potential
novel DILI biomarkers in drug development and clinical
practice.
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